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SUMMARY AND CONCLUSIONS
The transmission of the human immunodeficiency virus (HIV) by bloodproducts was a disas-
trous complication of substitution therapy for haemophilia A. Introduction of viral inactivation
procedures provided effective methods to prevent HIV seroconversion. Nevertheless, hepatitis
C virus (HCV) appeared not to be completely inactivated and administration of factor VIII con-
centrates howed to be associated with immune abnormalit ies in HIV negative haemophil ia A
patients.
The introduction of murine monoclonal antibodies for the production of ultrapure factor VIII
concentrates in combination with viral inactivation prclcedures was the next step to further
improve the safety of substitution therapy. The risk of viral transmission has been minimized in
this way. Furthermore, immune abnormalities have been reported to be absent in a cohort of pre-
viously untreated patients receiving these ultrapure concentrates. This thesis deals with the
immune abnormalities in HIV negative haemophilia A patients who had been treated with inter-
mediate purity factor VIII concentrates for approximately nine years, and their course after
treatment had been changed to a monoclonal purified product.
An overview tiom thc l iterature of the observcd immune abnormalit ies in HIV negative patients
with haemophilia A is given in chapter l. An attempt was made to relate the reported immune
abnormalities to the steps that can be distinguished in the normal immune reaction. Thus,
various steps of the normal immune rcsponse that are affected can be rdentified. Most of the
reported abnormalities regarded lymphocyte subsets and their function, both by in vivo or in
vitro testing. A multifactorial cause as explanation for the immune abnormalities seems to be
most l ikely. However, despite nunrerous tudies on this subject he knowledge sti l l  remains frag-
mentary.
Aim of the studies in the thesis was to identify immune parameter abnormalit ies in a group
of multitranstuscd patients with severc hacmophil ia A, all treated consecutively with an inter-
mediate purity and a heat-treated intcrmediate purity tactor VIII concentrate, and the course of
these abnormalities after treatment had been changed to a monoclonal purified product.
Analysis of specific changes in lymphocyte subset compilation might clarify the underlying
mechanism of the abnormalities found.
First, the efficacy and safety of the monoclonal purified factor VIII concentrate were assessed
during five year follow-up (chapter 2). The monoclonal purified factor VIll concentrate showed
to be similarly effective as compared with the previously administered concentrates. No HIV
inf-ection, no factor VIII inhibitor and no allergic reactions were denronstrated. For the other
viruses tested, most patients showed serologic evidence of previous infection at start of the
study. Elevated levels of l ivcrenzymes were seen in most patients at any time, these levels fluc-
tuated in time in individual patients. Conclusions on the course of liverenzymes for the whole
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group could not be drawn. The appendix reports on human anti-mouse immunoglobulin G
(HAMA) formation in one patient concomitant with treatment with the monoclonal purified
concentrate, probably due to the small amount of murine anti-factor VIII present in this product.
The course of lymphocyte subsets during two years after treatment changed from an interme-
diate purity factor VI1I concentrate to the monoclonal purified product is shown in chapter 3.
During treatment with the ultrapure concentrate a decrease of HLA-DR expression on non B-
lymphocytes during the first year, and a decrease of CD4-CD8 ratio over two years was seen.
The decrease in HLA-DR expression is compatible with a decreased immune stimulation. No
satisfactory explanation is available for the lowering of the CD4-CDS ratio. Furthermore, a
remarkable increase in the number of platelets during follow-up was observed. This might also
reflect a lower level of immune stimulation.
In chapter 4 the relation between CD4-CD8 ratio and the consecutively administered concentra-
tes is analyzed. The homogenous group of previously treated patients showed an increase in
CD4-CD8 ratio when they received a heat-treated intermediate purity factor VIII concentrate
and a temporary decrease atfer this product had been replaced by an ultrapure concentrate, these
changes were apparently related to the subsequently applied concentrates. This finding provides
supportive evidence that immune modulation may depend on the specific concentrates that are
used.
Supportive evidence of the supposed relation between concentrate purity and immune abnorma-
lities was obtained by comparing two groups of patients that differed only with respect to purity
of the factor VIII products used. The results of this study are summarized in chapter 5. One
group had been exclusively treated with cryoprecipitate and the other group had been treated
with the concentrates as described above. Both patient groups showed immune abnormalities as
compared with healthy matched controls. Elevated numbers of T:-lymphocytes and increased
numbers of HLA-DR expressing T-lymphocytes were found only in patients who received con-
centrates. Since all patients were positive for hepatitis C virus differences between groups
cannot be explained by infection with this virus.
To define the part of the immune reaction that is involved in the abnormalities found, a niore
extensive lymphocyte subset analysis was performed as described in chapter 6. Patients, com-
pared with age-matched-controls, howed elevated numbers of T-lymphocytes and an increase
in the number of CDS positive cells expressing activation markers HLA-DR, CD25, CD38 and
CD7l. This might be the result of chronic viral infections. However, considering the results,
reported in chapter5 it is less Iikely that hepatit is C virus is the cause of an elevated numberof
T-lymphocytes and./or increased activation marker expression on T-cells. A remarkable obser-
vation was an age related elevation of the number of CD4-CD45RO double positive
lymphocytes in patients, which was not demonstrated in controls. This finding might reflect the
large amounts of foreign proteins infused during for many years before treatment had been
changed to a monoclonal purified product.
During immune activation elevated serum levels of the soluble IL-2 receptor (sIL-2R) may indi-
cate the proliferative phase of the immune response and serum levels of soluble CD8 (sCDS) the
effector phase. Serum levels of sIL-2R and sCD8 before, and at two and five years of changing
treatment to the monoclonal purified concentrate are described in chapter 7. sIL-2R and sCDS
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levels were elevated in patients treated with an intermediate purity concentrate. A decrease in
sIL-2R became evident only after five years treatment with the ultrapure product, while sCDS
levels remained unchanged. These findings suggest a change in the proliferative phase of the
immune response without a similar change in the efTector phase.
Conclusions
The monoclonal purified factor VIII concentrate is efficacious in previously treated hae-
mophilia A patients. It is probably as effective as the less pure products used before in
these patients, as far as this conclusion is permitted from a historical comparison.
During treatmcnt with this monoclonal purified factor VIII concentrate no HIV transmis-
sion, allergic reactions and lactor VIII inhibitor fbrmation were demonstrated in the
multitransfused haemophilia A patients. Human anti-mouse immunoglobulin G concomi-
tant with the use of the monoclonal purified factor VIII concentrate was seen in one of 22
patients without any clinical fcatures. Overall, preexistent abnormalit ies of l iverenzymes
remained unchanged over a pcriod of five years.
Abnormalities due to treatment with intermediate purity factor VIII concentrates in the
well described homogenous group of HIV negative haemophiliacs comprised of changes
in CD4 and CD8 positive lymphocyte subsets, expression of stimulation marker HLA-DR
on T:lymphocytes, and elevated serum levels of soluble IL-2 receptor and soluble CD8.
During the first year of treatment with the ultrapure factor VIII concentrate a decrease of
HLA-DR expression suggests a lower level of immune stimulation. A decrease in sIL-2R
serum levels after f ive years, while sCD8 levels remained unchanged, suggest activation
in the effector phase that coincides with normalization in the proliferation phase. Besides,
the course of CD4-CDS ratio in this patient group seemed to be related to the purity of the
two consecutively applied concentrates.
Immune abnormalities found in patients with haemophilia A who had been treated exclu-
sively with cryoprecipitate were comparable with the findings in patients treated with
intermediate purity concentrates, except fbr differences in numbers of T-lymphocytes and
expression of stimulation markers on T-lymphocytes. These differences are not likely to
be caused by hepatit is C virus.
Lymphocyte subsets analysis at five years of treatment with the monoclonal purified pro-
duct showed abnormalities that consisted of elevatcd numbers of Tlymphocytes, and CD8
positive subsets that express activation markers. Both result from stimulation of the
immune system. An age related elevation of CD4 memory cells in the multitransfused
HIV negative patients might reflect the amount of foreign proteins infused over many
years.
Despite available evidence of immune abnormalit ies in HIV negative haemophil iacs, and more






dence that these findings are of clinical significance. This lack of clinical consequences might in
part be covered because of the high rate of HIV related morbidity and mortality in the haemo-
philia population. But, as long as such evidence of the clinical consequences of immune
abnormalities is not available, the choice of a factor VIII concentrate for substitution therapy in
HIV negative haemofhiliacs should primarily be based on the viral safety of the product. The
processing of ultrapure products has showed to be contributive only with this respect.
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